

23 October 2023 | 15:30 – 16:30 | Space 4 | level 0

A background image showing a healthcare professional, likely a nurse or doctor, wearing a blue surgical cap, a light blue face mask, and white gloves. They are holding a small vial or syringe and looking upwards. The setting appears to be an operating room or a clinical laboratory with medical equipment visible in the background.

Evidence-based, cerebroprotective treatment strategies in neurotrauma and delirium

Chair: Katarzyna Kotfis (Poland)

- **Can the devil be driven out of critically ill patients? –
Introducing a new cerebroprotective treatment option**
Wojciech Dabrowski (Poland)
- **Multimodal treatment strategies for TBI patients –
Why do we need them?**
Helmut Trimmel (Austria)

“Outcomes – Extraordinary cases in Neurorecovery”

Exclusively for participants of the symposium.

Visit our EVER Satellite Symposium and you will receive a new booklet with highly interesting case reports and case series results. The content of this booklet focuses on **extraordinary cases in neurorecovery** after **traumatic brain injury**, ischemic and hemorrhagic stroke, and all related complications.



SMALL MOMENT. BIG DIFFERENCE.

Last month, Paul was suffering from cognitive and motor impairment.
Today, he's making his next big move.

- Improvement of motor functions
- Early recovery after stroke
- Regain full independence
- Increase quality of life

Muresanu, et al., 2016

ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.



Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.